Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report

doi:10.12998/wjcc.v10.i16.5420

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3767)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

231

WORD

HTML

1409

Figures (1-4)

279

Tables (1-1)

619

Sum=2623

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

397

Download

747

Sum=1144

Jun 6, 2022 (publication date) through Feb 4, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jun 6, 2022; 10(16): 5420-5427
Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5420

Full Size Figure Download Figure

Figure 4 PET- computed tomography examinations at different time after second-line treatment. Persistent remission of perigastric lymph nodes.

Citation: Liu M, Luo C, Xie ZZ, Li X. Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report. World J Clin Cases 2022; 10(16): 5420-5427
URL: https://www.wjgnet.com/2307-8960/full/v10/i16/5420.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i16.5420